The FDA has approved a generic version of a GLP-1 drug, a daily injection, for people with type 2 diabetes. However, it is unclear if this approval is specifically for a generic version of a particular brand name drug, as some reports mention liraglutide, while others reference different medications such as Mounjaro and Zepbound. The approval may have implications for treatments related to weight loss and obesity, in addition to diabetes management.